Provided by Tiger Trade Technology Pte. Ltd.

Aptevo Therapeutics

1.77
+0.01000.57%
Volume:10K
Turnover:17.75K
Market Cap:3.19M
PE:-0.03
High:1.80
Open:1.80
Low:1.77
Close:1.76
52wk High:35.64
52wk Low:1.37
Shares:1.80M
Float Shares:1.70M
Volume Ratio:0.46
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-58.0829
EPS(LYR):-82.2951
ROE:-420.34%
ROA:-111.49%
PB:0.53
PE(LYR):-0.02

Loading ...

Aptevo Therapeutics advances trispecific candidate toward clinical development

TIPRANKS
·
Sep 24

Aptevo Therapeutics - Expects to Enter Ind-Enabling Studies for Apvo451 in 1h2027 - SEC Filing

THOMSON REUTERS
·
Sep 24

Aptevo Targets IND-Enabling Studies for Trispecific Cancer Drug Apvo451 in 1H 2027

Reuters
·
Sep 24

Aptevo Therapeutics Holds Special Shareholder Meeting

Reuters
·
Sep 24

Aptevo AML data ‘highly encouraging,’ says Roth Capital

TIPRANKS
·
Sep 03

Aptevo Therapeutics Reports Early Data for Blood Cancer Therapy; Shares Fall

Reuters
·
Sep 03

Aptevo Therapeutics Shares Down 16.2% Premarket After Co Announces Leukemia Drug Study Update

THOMSON REUTERS
·
Sep 03

Aptevo Therapeutics - Regulatory Interaction Planned for 1H27 for Mipletamig in Frontline Aml - SEC Filing

THOMSON REUTERS
·
Sep 03

Aptevo Therapeutics - Rainier Study Dose Optimization Phase Expected to Complete by Year-End - SEC Filing

THOMSON REUTERS
·
Sep 03

Aptevo Therapeutics’ mipletamig triplet shows 93% benefit in leukemia

TIPRANKS
·
Sep 03

Aptevo Says Mipletamig Triplet Posts 93% Clinical Benefit Rate in Frontline TP53-Mutated AML Trial

Reuters
·
Sep 03

Aptevo Therapeutics Announces Special Shareholder Meeting

Reuters
·
Sep 01

Aptevo Therapeutics files to sell 6.44M shares of common stock for holders

TIPRANKS
·
Aug 22

Aptevo Therapeutics Held Annual Shareholder Meeting

Reuters
·
Aug 22

Analysts Offer Insights on Healthcare Companies: Aptevo Therapeutics (APVO) and Jasper Therapeutics (JSPR)

TIPRANKS
·
Aug 18

Aptevo Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Aptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) Estimate

Benzinga Earnings
·
Aug 14

Aptevo Net Loss Widens to $13.1 Million in FY26 H1; Operating Cash Outflow Narrows to $13.4 Million

Reuters
·
Aug 14

Aptevo Wins $1.5 Million CARE Fund Grant for Apvo451 IND-Enabling Work

Reuters
·
Aug 14

Aptevo Names Mary Janatpour Chief Scientific Officer

Reuters
·
Aug 14